ETFs
I
IRLA
IRulya Therapeutics Inc
38.42
+4.67+13.84%Opening12:06 10/20 EDT
OPEN/PREV CLOSE34.99/33.75
TODAY RANGE34.96-40.35
VOL107.16K
MARKET CAP416.53M
52 WEEK RANGE15.10-909.98
AVG VOL (3M)29.78K
% TURNOVER0.98%
TURNOVER--
P/E (TTM)-0.3056
% RANGE15.97%
EPS(TTM)-125.7083
P/E(FORWARD)-4.1774
P/B0.3602
BVPS106.67
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP380.32M
SHARES OUTSTANDING10.84M
NEXT EARNINGS11/10-11/16
FREE FLOAT9.90M
LOT SIZE1
EX-DATE06/30/2026
News
Press Releases
Financial Reports
Profile
TipRanks·1d ago
IRulya updates rare pulmonary LAM-001 development strategy
Dow Jones·10/12 21:08
*News On Quince Therapeutics Inc. (QNCX) Now Under IRLA
NASDAQ·10/10 01:44
Raymond James Initiates Coverage of Quince Therapeutics at Outperform
TipRanks·10/09 12:17
Quince Relaunches as IRulya Therapeutics with New Leadership
TipRanks·10/09 12:16
Quince Therapeutics changes name to IRulya Therapeutics
Dow Jones·10/09 11:35
Quince Therapeutics Price Target Announced at $72.00/Share by Raymond James
TipRanks·10/09 10:35
Quince Therapeutics initiated with an Outperform at Raymond James
TipRanks·10/06 21:18
Quince Shareholders Approve New Equity and Stock Plans
TipRanks·10/02 11:58
Quince Therapeutics Announces Conditional Board Restructuring Plans
TipRanks·09/30 08:05
Leerink Partners Reaffirms Their Buy Rating on Quince Therapeutics (QNCX)
NASDAQ·09/24 18:33
Rodman & Renshaw Initiates Coverage of Quince Therapeutics with a Buy
TipRanks·09/24 13:46
CoreWeave upgraded, Etsy downgraded: Wall Street’s top analyst calls
Benzinga·09/24 11:56
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Same Industry
Name/Symbol
Change%
Price